Bullish Case: BTIG's Buy/$26 target (Sep 23) anchors a re-rating case: Himalayas-1 Phase 3 enrollment progressing, enozertinib adds a second late-stage path, and $387.6M cash funds both. The Helium density peaks at $12-13 with meaningful right-tail mass toward $15-16; back-month IV (~92-97) below the front (~205) implies the market expects the fear premium to decay without a downside event, leaving room for a grind toward $15.

Bearish Case: Term structure is backwardated and puts traded 4122% of call volume—a stark hedging signal. Deep OTM puts carry 400-500 IV and Helium's left tail extends to $8-11. Zero insider buys vs. 12 CFO sells plus guru trimming, a Q2 EPS miss, and $13.37 sitting ~11% below the 52-week high suggest institutional skepticism while the trial is years from data (H1 2028).

Potential Outcomes:

1. ~35%: Rangebound $12-14.50 as enrollment news trickles; front IV decays, backwardation flattens (falsify: realized move >±15%).
2. ~25%: Bearish leg to $10-11.50 on put-flow-follow-through, financing, or enozertinib/regulatory concerns (falsify: put IV compresses sharply).
3. ~25%: Bullish $15-17 on analyst upgrades, positive enrollment/ESMO read-throughs, or Pfizer-partnership speculation (falsify: BTIG-style targets fail to attract volume).
4. ~15%: Sharp tail move <$9 or >$18 on binary pipeline/news shock (falsify: skew and back-month IV stay stable).

September 30, 2026